ALVR News and Press, AlloVir Inc. From 06/21/23

AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. AlloVir also intends to grant the underwriters a 30-day option to purchase up to an additional 15...

2023-06-09 11:04:53 ET Shares of AlloVir (NASDAQ: ALVR) are up more than 48% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $3.96, then rose to as high as $6.12 on Wednesday. Th...

Posoleucel demonstrated clinically meaningful reductions in BK viral load as compared to placebo with the greatest antiviral activity seen among patients with higher viral loads and those who received more frequent posoleucel dosing At Week 24, the percentage of patients with a ≥1-...

2023-05-16 19:09:57 ET Summary Many US-listed biotech companies are likely to trade cheaply relative to their prospects as a result of concerns about the stability of the US banking system and the risk of a recession. I believe biotech investors should consider a "Buy" rating on A...

- Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the a...

2023-05-04 10:27:07 ET AlloVir press release ( NASDAQ: ALVR ): Q1 GAAP EPS of -$0.44 beats by $0.02 . As of March 31, 2023, AlloVir had cash, cash equivalents, and short-term investments of $202.6 million, compared with cash, cash equivalents, and short-term investment...

Company’s three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024 Positive results from a randomized, double-blind, placebo-controlled Phase 2 study of posoleucel in kidney transpl...

AlloVir, Inc. (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2023 Health Care Conference in Las Vegas, NV on Tuesday, May 9, 2023, at 8:40...

Day 400 non-relapse mortality was 0% Previously reported data from the 14-week primary endpoint showed low rates of clinically significant viral infections and diseases in this high-risk patient population despite the expected high rates of viral reactivation Global Phase 3 pivota...

AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings more than two decades of experience leading the manufacturing of biologic and gene the...